Universal CNK-UT Therapy for Refractory aGVHD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Universal CNK-UT Therapy for Refractory aGVHD — Stella

Recruiting

Back to Acute Graft-versus-Host Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian

The first affiliated hospital of zhejiang university, school of medicine., Hangzhou, Zhejiang

Key details

Phase

Early testing

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

ST Phi Therapeutics Co., Ltd

Enrollment target

~23 participants

Started

December 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

14 Years – 70 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov